Endothelial von Willebrand factor regulates angiogenesis

Blood

Volumn 117, Issue 3, 2011, Pages 1071-1080

  Starke, Richard D ^a   Ferraro, Francesco ^b   Paschalaki, Koralia E ^a   Dryden, Nicola H ^a   McKinnon, Thomas A J ^c   Sutton, Rachel E ^a   Payne, Elspeth M ^a,d   Haskard, Dorian O ^a   Hughes, Alun D ^a   Cutler, Daniel F ^b   Laffan, Mike A ^c   Randi, Anna M ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ARGINYLGLYCYLASPARTIC ACID; MESSENGER RNA; PROTEIN SUBUNIT; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR;

ANGIODYSPLASIA; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL; CELL EXPANSION; CELL MIGRATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DENSITY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL; VASCULARIZATION; VON WILLEBRAND DISEASE;

EID: 78951492972     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-264507     Document Type: Article

References (53)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9(6):653-660.
2. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009;6(9):507-518.
3. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
4. Gerhardt H. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis. 2008;4(4):241-246.
5. Thomas M, Augustin HG. The role of the angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12(2):125-137.
6. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-1180. (Pubitemid 27010101)
7. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18(38):5356-5362. (Pubitemid 29462372)
8. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002;99(17):11205-11210.
9. Hodivala-Dilke K. alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol. 2008;20(5):514-519.
10. Somanath PR, Malinin NL, Byzova TV. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis. 2009;12(2):177-185.
11. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci U S A. 1987;84(18):6471-6475.
12. Huang J, Roth R, Heuser JE, Sadler JE. Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. Blood. 2009;113(7):1589-1597.
13. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56:173-191.
14. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449-1459.
15. Denis CV, Andre P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proc Natl Acad Sci U S A. 2001;98(7):4072-4077.
16. Pendu R, Terraube V, Christophe OD, et al. Pselectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108(12):3746-3752.
17. Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;46(2):185-190.
18. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64(2):403-413.
19. Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler DF. Formation and function of Weibel-Palade bodies. J. Cell Sci. 2008;121(Pt 1):19-27.
20. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost. 1993;70(3):546.
21. Park SO, Wankhede M, Lee YJ, et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009;119(11):3487-3496.
22. Junquera F, Saperas E, de T, I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol. 1999;94(4):1070-1076. (Pubitemid 29173630)
23. Bauditz J, Lochs H. Angiogenesis and vascular malformations: antiangiogenic drugs for treatment of gastrointestinal bleeding. World J Gastroenterol. 2007;13(45):5979-5984. (Pubitemid 350238263)
24. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-2760.
25. Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008;111(7):3498-3506.
26. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95(16):9524-9529. (Pubitemid 28506264)
27. Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol. 2001;11(18):1392-1402.
28. Huang MT, Mason JC, Birdsey GM, et al. Endothelial intercellular adhesion molecule (ICAM)-2 regulates angiogenesis. Blood. 2005;106(5):1636-1643.
29. Martinez-Perez M, Hughes AD, Thom SA, Parker KH. Improvement of a retinal blood vessel segmentation method using the Insight Segmentation and Registration Toolkit (ITK). Conf Proc IEEE Eng Med Biol Soc. 2007;2007:892-895.
30. Smith TG Jr, Lange GD, Marks WB. Fractal methods and results in cellular morphology-dimensions, lacunarity and multifractals. J Neurosci Methods. 1996;69(2):123-136.
31. Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis. 2009;12(3):267-274.
32. Davis GE. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun. 1992;182(3):1025-1031.
33. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15(4):392-400.
34. Thomas M, Felcht M, Kruse K, et al. Angiopoietin-2 stimulation of endothelial cells induces alphaVbeta3 integrin internalization and degradation. J Biol Chem. 2010;285(31):23842-23849.
35. Anghelina M, Krishnan P, Moldovan L, Moldovan NI. Monocytes and macrophages form branched cell columns in matrigel: implications for a role in neovascularization. Stem Cells Dev. 2004;13(6):665-676. (Pubitemid 40052643)
36. Tigges U, Hyer EG, Scharf J, Stallcup WB. FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development. 2008; 135(3):523-532.
37. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood. 2007;109(5):1801-1809.
38. Hodivala-Dilke KM, Reynolds AR, Reynolds LE. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res. 2003;314(1):131-144.
39. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
40. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8(1):27-34.
41. Reynolds AR, Reynolds LE, Nagel TE, et al. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res. 2004;64(23):8643-8650.
42. White DP, Caswell PT, Norman JC. alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration. J Cell Biol. 2007;177(3):515-525.
43. Dalton SL, Scharf E, Briesewitz R, Marcantonio EE, Assoian RK. Cell adhesion to extracellular matrix regulates the life cycle of integrins. Mol Biol Cell. 1995;6(12):1781-1791.
44. Yu Q, Stamenkovic I. Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol. 2001;158(2):563-570. (Pubitemid 32158617)
45. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70(6):2213-2223.
46. Feng Y, Vom HF, Pfister F, et al. Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thromb Haemost. 2007;97(1):99-108.
47. Redondo P, Martinez-Cuesta A, Quetglas EG, Idoate M. Active angiogenesis in an extensive arteriovenous vascular malformation: a possible therapeutic target? Arch Dermatol. 2007;143(8):1043-1045. (Pubitemid 47296081)
48. O'Brien JR. Familial capillary fragility (diffuse capillary teleangiectasia). Proc Int Soc Hematol. 1953;20:546-548.
49. Blackburn EK. Primary capillary haemorrhage (including von Willebrand's disease). Br J Haematol. 1961;7:239-249.
50. Koscielny JK, Latza R, Mursdorf S, et al. Capillary microscopic and rheological dimensions for the diagnosis of von Willebrand disease in comparison to other haemorrhagic diatheses. Thromb Haemost. 2000;84(6):981-988.
51. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest. 2004;113(4):516-527. (Pubitemid 38542501)
52. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286(5449):2511- 2514. (Pubitemid 129515972)
53. Lian J, Guoping C, Shapiro SS, Tran LP, Beacham DA. Glycoprotein Ibα can mediate endothelial cell migration on von Willebrand Factorcontaining substrata. Exp Cell Res. 1999;252(1):114-122.